Organigram (US:OGI) ZACKS·2025-05-13 00:15Core Viewpoint - OrganiGram reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.03, marking a significant earnings surprise of -66.67% [1][2] Financial Performance - OrganiGram's revenues for the quarter ended March 2025 were $45.69 million, exceeding the Zacks Consensus Estimate by 8.09% and showing a year-over-year increase from $27.91 million [2] - Over the last four quarters, the company has surpassed consensus revenue estimates three times [2] Stock Performance and Outlook - OrganiGram shares have declined approximately 26.7% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The company's earnings outlook is currently unfavorable, leading to a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Future Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $45.73 million, and for the current fiscal year, it is -$0.16 on revenues of $166.74 million [7] Industry Context - The Medical - Products industry, to which OrganiGram belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, suggesting potential challenges for stock performance [8]